Patents Assigned to Expression Pathology Incorporated
  • Patent number: 8728753
    Abstract: Peptides from the Insulin-Like Growth Factor 1 Receptor (IGF-1R) protein are provided that are particularly advantageous for quantifying the IGF-1 R protein directly in biological samples, such as samples fixed in formalin. The ionization characteristics of the peptides also are disclosed. The peptides may be used in Selected Reaction Monitoring (SRM) mass spectrometry methods, also referred to Multiple Reaction Monitoring (MRM) mass spectrometry methods. The samples are chemically preserved and fixed, such as tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample may be prepared from the biological sample and the IGF-IR protein is quantitated by the method of SRM/MRM mass spectrometry by quantitating one or more of the described peptides.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: May 20, 2014
    Assignee: Expression Pathology Incorporated
    Inventors: David B. Krizman, Todd Hembrough, Sheeno Thyparambil
  • Patent number: 8609345
    Abstract: The invention provides methods for diagnosing diseases such as cancer and other conditions using biological samples. Liquid Tissue samples prepared from histopathologically prepared tissue obtained from a subject surprisingly can be used to identify and, optionally, to quantify analytes that are diagnostic of the presence of a disease, condition or syndrome in the subject.
    Type: Grant
    Filed: May 25, 2006
    Date of Patent: December 17, 2013
    Assignee: Expression Pathology Incorporated
    Inventors: David B. Krisman, Marlene M. Darfler, Thomas G. Guiel, Casimir P. Eitner